Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials

Open Access

Peer-reviewed

Research Article

Charles Ferte ,

* E-mail: chferte@hotmail.com

Affiliations Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France, SITEP (Phase 1 unit), Département de Médecine, Institut Gustave Roussy, Villejuif, France
⨯
Jean-Charles Soria,

Affiliation SITEP (Phase 1 unit), Département de Médecine, Institut Gustave Roussy, Villejuif, France
⨯
Nicolas Penel

Affiliations Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France, Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniques, Université Lille II, Lille, France
⨯

Reader Comments (0)

Phase I clinical investigation
Is the Subject Area "Phase I clinical investigation" applicable to this article?

Thanks for your feedback.
Oncology
Is the Subject Area "Oncology" applicable to this article?

Thanks for your feedback.
Toxic agents
Is the Subject Area "Toxic agents" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.